Поиск
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.

Список литературы

  1. Азарова В.Н., Хамаганова И.В., Поляков А.В. Генетика псориаза.// Российский журнал кожных и венерических болезней -2003г., -№ 6, с.29-33
  2. Бакулев А.Л., Знаменская Л.Ф., Хобейш М.М., Олисова О.Ю. Федеральные клинические рекомендации по ведению больных псориазом. – М., 2013. - 68с.
  3. Зверькова Ф.А. Болезни кожи детей. - СПб.: СОТИС, 1994, -236с.
  4. Кубанова А.А., Кубанов А.А., Дж.Ф. Николас, Л. Пьюиг, Дж. Принц, Катунина О.Р., Знаменская Л.Ф. Иммунные механизмы псориаза. Новые стратегии биологической терапии / Вестник дерматологии и венерологии. – 2010, №1. – С.35-47.
  5. Кубанова А.А., Мурашкин Н.Н. Псориаз и псориазиформные состояния, как аспект современных клинических особенностей течения дерматозов в детском возрасте / Вестник дерматологии и венерологии. – 2011, №2. – С.38-43
  6. Молочков В.А. Псориаз и псориатический артрит / В.А. Молочков, В.В. Бадокин, В.И. Альбанова, В.А.Волнухин. – М., 2007. – 240с.
  7. Мурашкин Н.Н., Глузмин М.И., Хотко А.А. и соавт. Факторы риска возникновения псориаза у детей, возрастные особенности клиники и течения заболевания / Современные проблемы дерматовенерологии, иммунологии и врачебной косметологии. – 2010, №5 (12). – С.30 – 35.
  8. Мурашкин Н.Н., Мазитова Л.П., Намазова Л.С. Особенности ангиогенеза и обоснование патогенетической терапии у детей, страдающих псориазом / Вестник дерматологии и венерологии. – 2009, № 1. – С.81-87.
  9. Хёгер П.Г. Детская дерматология. – М., 2013. – 634с.
  10. A multicenter, randomized, double-dummy, double-blind study evaluating two doses of adalimumab versus methotrexate (MTX) in paediatric subjects with chronic plaque psoriasis. In: ClinicalTrials.gov, Identifier: NCT01251614. Last updated April 8, 2014. URL http://www.clinicaltrials.gov/ct2/show/NCT01251614?term=adalimumab+psoriasis&rank=8. (last accessed: 26 June 2014).
  11. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the of Efficacy and Safety of Ustekinumab in the Treatment of Adolescent Subjects With Moderate to Severe Plaque-typePsoriasis (CADMUS). In: ClinicalTrials.gov, Identifier: NCT02166203. Last updated: June 17, 2014. URL http://www.clinicaltrials.gov/ct2/show/
  12. Abdel Naser MB, Wollina U, El Okby M, El Shiemy S. Psoralen plus ultraviolet A irradiation-induced lentigines arising in vitiligo: involvement of vitiliginous and normal appearing skin. Clin Exp Dermatol. 2004;29:380–2.
  13. Adamski Z, Dudziak M, Zakrzewska K. Etanercept in dermatological practice - authors’ own experience in the treatment of psoriasis vulgaris and psoriatic arthritis. Post Dermatol Alergol 2011; 28: 435–441.
  14. Ahini RT, Camp NJ, Cork MJ, et al. Novel genetic association between the corneodesmin gene (MHC S) gene and susceptibility to psoriasis. Hum Mol Genet. 1999;8:1135-1140.
  15. Alen MH, Veal C, Faassen A, et al. A non-HLA gene within the MHC in psoriasis. Lancet. 1999;353:1589-1590.
  16. Alli N, Gungor E, Karakayali G, Lenk N, Artuz F. The use of cyclosporinin a child with generalized pustular psoriasis. Br J Dermatol 1998; 139:754–755.
  17. Al-Shobaili H, Al-Khenaizan S. Childhood generalized pustular psoriasis: Successful treatment with isotretinoin. Pediatr Dermatol 2007; 24:563–564.
  18. Alvarez AC, Rodriguez-Nevado I, De Argila D et al. Recalcitrant pustular psoriasis successfully treated with adalimumab. Pediatr Dermatol 2011;28: 195–197.
  19. Andreben C, Henseler T. Die Erblichkeit der psoriasis: Eine analyse von 2035 familienanamnesen. Hautarzt. 1982;33:214-217.
  20. Armin S, Cahvoshzadeh Z, Karimi A, Tajeddini A, Toosi P. Mucocutaneous candidiasis or psoriasis? A case report. J Res Med Sci 2007; 12: 96–99.
  21. Ashcroft DM, Po AL, Williams HC, Griffiths CE. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ. 2000 Apr 8;320(7240):963-7.
  22. Asumalahti K, Laitinen T, Itkonen-Vatius R, et al. A candidate gene for psoriasis near HLA-C, HCR (Pg8), is highly polymorphic with a disease associated susceptibility allele. Hum Mol Genet. 2000;9(10):1533-1542.
  23. Bahram S, Bresnahan M, Geraghty DE, et al. A second lineage of mammalian major histocompatibility complex class I gene. Proc Natl Acad Sci USA. 1994;91:6259-6263.
  24. Bahram S, Mizuki N, Inoko H, et al. Nucleotide sequence of the human MHC class I MIC gene. Immunogenetics. 1996;44:80-81.
  25. Balak DM, Oostveen AM, Bousema MT et al. Effectiveness and safety of fumaric acid esters in children with psoriasis: a retrospective analysis of 14 patients from The Netherlands. Br J Dermatology 2013; 168: 1343–1347.
  26. Beattie PE, Lewis-Jones MS. A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases. Br J Dermatol. 2006;155:145–51.
  27. Beikert FC, Augustin M, Radtke MA. Etanercept in juvenile psoriasis. Hautarzt 2012; 63: 406–410.
  28. Beylot C, Puissant A, Bioulac P, et al. Particular clinical features of psoriasis in infants and children. Acta Dermatol Venereol (Stockh). 1979;59(87):95-97.
  29. Borska L, Fiala Z, Krejsek J, et al. Immunologic changes in TNF-alpha, sE-selectin, sPselectin, sICAM-1, and IL-8 in pediatric patients treated for psoriasis with the Goeckerman regimen. Pediatr Dermatol. 2007;24:607–12.
  30. Brandrup F, Hauge M, Henningsen J, et al. 15. Psoriasis in an unselected series of twins. Arch Dermatol. 1978;114:874-878.
  31. Brenner W, Gschnait F, Mayr WR, et al. HLA B13, B17, B37 and Cw6 in psoriasis vulgaris: association with the age of onset. Arch Dermatal Res. 1978;262:337-339.
  32. Burden AD, Javed S, Bailey M, et al. Genetics of psoriasis: paternal inheritance and a locus on chromosome 6p. J Invest Dermatol. 1998;110;958-960.
  33. Burden AD. Indentifying a gene for psoriasis on chromosome 6 (Psors 1). Br J Dermatol. 2000;143:237-241.
  34. Callen JP, Jackson JH. Adalimumab effectively controlled recalcitrant generalized pustular psoriasis in an adolescent. J Dermatolog Treat 2005; 16:350–352.
  35. Capon F, Novelli G, Samprini M, et al. Searching for psoriasis susceptibility genes in Italy: genome scan and evidence for a new locus on chromosome 1. J Invest Dermatol. 1999;112:32-35.
  36. Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identifcation of IL23R as psoriasis- risk genes. Am J Hum Genet. 2007;80:273-290.
  37. Chao PH, Cheng YW, Chung MY. Generalized pustular psoriasis in a 6-week-old infant. Pediatr Dermatol 2009; 26: 352–354.
  38. Chaves YN, Cardoso DN, Jorge PF, Follador I, Oliveira Mde F. Childhood pustular psoriasis: case report. An Bras Dermatol 2010; 85: 899–902.
  39. Cheng L, Zhang SZ, Xiao CY, et al. The A5.1 allele of the major histocompatibility complex chain-related geneA is associated with psoriasis vulgaris in Chinese. Br J Dermatol. 2000;143:324-329
  40. Collin B, Vani A, Ogboli M, Moss C. Methotrexate treatment in 13 children with severe plaque psoriasis. Clin Exp Dermatol 2009; 34: 295–298.
  41. Cordoro KM. Management of childhood psoriasis. Adv Dermatol. 2008; 24:125–69.
  42. Corrales IL, Ramnarine S, Lansang P. Treatment of Childhood Psoriasis with Phototherapy and Photochemotherapy Clinical Medicine Insights: Pediatrics 2013:7-33.
  43. Coven TR, Burack LH, Gilleaudeau R, Keogh M, Ozawa M, Krueger JG. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol. 1997;133:1514–22.
  44. Darley CR, Cunliffe WJ, Green CM, Hutchinson PE, Klaber MR, Downes N. Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris. Br J Dermatol. 1996;135:390–3.
  45. De Gruijl FR. The fundamental bases of phototherapy. Milan, Italy: OEMF Spa. 1986:153–170.
  46. de Jager ME, de Jong EM, van de Kerkhof PC, Seyger MM. Efficacy andsafety of treatments for childhood psoriasis: a systematic literature review.J Am Acad Dermatol 2010; 62: 1013–1030.
  47. Dhar S, Banerjee R, Agrawal N, Chatterjee S, Malakar R. Psoriasis in children: an insight. Indian J Dermatol. 2011;56:262–5.
  48. Dini V, Barbanera S, Romanelli M. Efficacy of adalimumab for the treatment of refractory paediatric acrodermatitis continua of hallopeau. Acta Derm Venereol 2013; 93: 588–589.
  49. Dixit S, Shumack S, Fischer G. Ustekinumab in the treatment of severe paediatric psoriasis. Australas J Dermatol 2013; 54: 147.
  50. Dogra S, De D. Phototherapy and photochemotherapy in childhood dermatoses. Indian J Dermatol Venereol Leprol. 2010;76:521–6.
  51. Dogra S, Handa S, Kanwar AJ. Methotrexate in severe childhood psoriasis.
  52. Dogra S, Kaur I. Childhood psoriasis. Indian J Dermatol Venereol Leprol. 2010;76:357– 65.
  53. Dogra S, Kumaran MS, Handa S, Kanwar AJ. Methotrexate for generalized pustular psoriasis in a 2-year-old child. Pediatr Dermatol 2005; 22:85–86.
  54. Duffy DL, Spelman LS, Martin NG. Psoriasis in Australian twins. J Am Acad Dermatol. 1993;29:428-434.
  55. Elder JT. Genome- wide association scan yields new insights into the immunopathogenesis of psoriasis. Genes immun. 2009;10(3):201-209.
  56. Enlund F, Samuelsson L, Enerback C, et al. Psoriasis susceptibility locus in chromosome region 3q21 identified in patients from southwest Sweden Eur J Hum Genet. 1999;7:783-790.
  57. Ergin S, Ersoy-Evans S, Sahin S, Ozkaya O. Acitretin is a safe treatment option for infantile pustular psoriasis. J Dermatolog Treat 2008; 19:341–343.
  58. Ersoy-Evans S, Altaykan A, Sahin S, Kolemen F. Phototherapy in childhood. Pediatr Dermatol. 2008;25:599–605.
  59. Fabrizi G, Guerriero C, Pagliarello C. Etanercept in infants: suberythrodermic, recalcitrant psoriasis in a 22 month-old child successfully treated with etanercept. Eur J Dermatol 2007; 17: 245.
  60. Farber E.M., Nall L. Childhood psoriasis.// Cutis. - 1999 Nov; 64(5):309-14.
  61. Farber EM, Bright RD, Nall ML. Psoriasis: a questionnaire survey of 2,144 patients. Arch Dermatol. 1968;98:248-259.
  62. Farber EM, McClintock Jr RP. A current review of psoriasis. Calif Med J. 1968;108:440.
  63. Farber EM, Nall L, Watson W. Natural history of psoriasis in 61 twin pairs. Arch Dermatol. 1974;109:207-211.
  64. Farber EM, Nall ML. Epidemiology: Natural history and genetics. In: 49 Roenigk HH, Maibach HI, eds. Psoriasis. 3rd ed. New York: Marcel Dekker; 1998:107-158.
  65. Farber EM, Nall ML. The natural history of psoriasis in 5600 patients. Dermatologica. 1974;148:1-18.
  66. Farnsworth NN, George SJ, Hsu S. Successful use of infliximab following a failed course of etanercept in a pediatric patient. Dermatol Online J 2005; 11: 11.
  67. Floristan U, Feltes R, Ramirez P, Alonso ML, de Lucas R. Recalcitrant Palmoplantar Pustular Psoriasis Treated with Etanercept. Pediatr Dermatol 2011; 28: 349–350.
  68. Fotiadou C, Lazaridou E, Giannopoulou C, Ioannides D. Ustekinumab for the treatment of an adolescent patient with recalcitrant plaque psoriasis. Eur J Dermatol 2011; 21: 117–118.
  69. Fotiadou C, Lazaridou E, Ioannides D. Management of psoriasis in adolescence. Adolesc Health Med Ther 2014; 5: 25–34.
  70. Fraga NA, Paim MdeF, Follador I, Ramos AN, Rego VR. Refractory erythrodermic psoriasis in a child with an excellent outcome by using etanercept. An Bras Dermatol 2011; 86: 144–147.
  71. Garg T, Chander R, Mittal S. Familial juvenile generalized pustular psoriasis:response to methotrexate. Skinmed 2011; 9: 190–191.
  72. Gazit E, Brenner S, Efter T, et al. HLA antigens in patients with psoriasis Tissue Antigens. 1978;12:195-199.
  73. Geel M.J. van, K. Mul, M.E.A. de Jager, P.C.M. van de Kerkhof, E.M.G.J. de Jong, M.M.B. Seyger Systemic treatments in paediatric psoriasis: a systematic evidence-based update. J Eur Acad Dermatol Venereol. 2015 Mar;29(3):425-37
  74. Gerdes S, Domm S, Mrowietz U. Long-term treatment with fumaric acid esters in an 11year-old male child with psoriasis. Dermatology 2011; 222:198–200.
  75. Gunther CH, Schmitt J, Wozel G. Successive use of fumaric acid esters forthe treatment of psoriasis vulgaris in a 14-year-old patient. Haut 2004; 15:28–30. (German).
  76. Gupta R, Gupta S. Methotrexate-betamethasone weekly oral pulse in psoriasis. J Dermatolog Treat 2007; 18: 291–294.
  77. Haftek M, Simon M, Kanitakis J, et al. Expression of corneodesmin in the granular layer and stratum corneum of normal and diseased epidermis Br J Dermatol. 1997;137:864-873.
  78. Hellgren L. Psoriasis: The prevalence in sex, age and occupational groups in total populations in Sweden. Morphology, inheritance and associations with other skin and кругьфешс diseases. Stockholm: Almqvist and Wiskell; 1967.
  79. Henseler T, Christophers E. Psoriasis of early and late onset: chracterisation of two types of psoriasis vulgaris.J Am Acad Dermatol. 1985;13:450-456.
  80. Hoang JK, Burruss J. Localized cutaneous Cryptococcus albidus infection in a 14-yearold boy on etanercept therapy. Pediatr Dermatol 2007; 24: 285–288.
  81. Hoger PH, Hamm H. Psoriasis vulgaris in children and adolescents: Pathogenesis,clinical manifestation and therapy. Monatsschrift fur Kinderheilkunde 2014; 162: 163–177.
  82. Ikaheimo I, Silvennoinen- Kassinen S, Karvonen J, et al. Immunogenetic profile of pseuriasis vulgaris: association with haplotypes A2, B13, Cw6, DR7, DQA1*0201 and A1, B17, Cw6, DR7, DQA1*0201. Arch Dermatol Res. 1996;288:363-367.
  83. Information for Healthcare Professionals: Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi).URL http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety- InformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm17 4474.htm. (last accessed: 26 June 2014).
  84. Ingram JR, Anstey AV, Piguet V. Combination treatment with a tumour necrosis factor antagonist and an oral retinoid: efficacy in severe acral psoriasis? Br J Dermatol 2012; 167: 949–951.
  85. Ivker RA, Grin-Jorgensen CM, Vega VK, Hoss DM, Grant-Kels JM. Infantile generalized pustular psoriasis associated with lytic lesions of the bone. Pediatr Dermatol 1993; 10: 277–282.
  86. Jain VK, Aggarwal K, Jain K, Bansal A. Narrow-band UV-B phototherapy in childhood psoriasis. Int J Dermatol. 2007;46:320–2.
  87. Jain VK, Bansal A, Aggarwal K, Jain K. Enhanced response of childhood psoriasis to narrow-band UV-B phototherapy with preirradiation use of mineral oil. Pediatr Dermatol. 2008;25:559–64.
  88. Jenisch S, Koch S, Henseler T, et al. Corneodesmin gene polymorphism demonstrates strong linkage disequilibrium with HLA and association with psoriasis vulgaris. Tissue Antigens. 1999;54:439-449.
  89. Johnson-Huang LM, Suarez-Farinas M, Sullivan-Whalen M, Gilleaudeau P, Krueger JG, Lowes MA. Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. J Invest Dermatol. 2010;130:2654–63.
  90. Juanqin G, Zhiqiang C, Zijia H. Evaluation of the effectiveness of childhood generalized pustular psoriasis treatment in 30 cases. Pediatr Dermatol 1998; 15: 144–146.
  91. Jury CS, McHenry P, Burden AD, Lever R, Bilsland D. Narrowband ultraviolet B (UVB) phototherapy in children. Clin Exp Dermatol. 2006;31:196–9.
  92. Kalla G, Goyal AM. Juvenile generalized pustular psoriasis. Pediatr Dermatol 1996; 13: 45–46.
  93. Kaur I, Dogra S, De D, Kanwar AJ. Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India. Pediatr Dermatol 2008; 25: 184–188.
  94. Kilic SS, Hacimustafaoglu M, Celebi S, Karadeniz A, Ildirim I. Low dose сyclosporin A treatment in generalized pustular psoriasis. Pediatr Dermatol 2001; 18: 246–248.
  95. Kim BS, Shin S, Youn JI, Lee YS. Treatment of erythrodermic psoriasis with etretinate. Ann Dermatol 1991; 3: 107–111.
  96. Kiszewski AE, De Villa D, Scheibel I, Ricachnevsky N. An infant with acrodermatitis continua of Hallopeau: successful treatment with thalidomide and UVB therapy. Pediatr Dermatol 2009; 26: 105–106.
  97. Kortuem KR, Davis MD, Witman PM, McEvoy MT, Farmer SA. Results of Goeckerman treatment for psoriasis in children: a 21-year retrospective review. Pediatr Dermatol. 2010;27:518–24.
  98. Kress DW. Etanercept therapy improves symptoms and allows tapering of other medications in children and adolescents with moderate to severe psoriasis. J Am Acad Dermatol 2006; 54: S126–S128.
  99. Kumar B, Dhar S, Handa S, Kaur I. Methotrexate in childhood psoriasis. Pediatr Dermatol 1994; 11: 271–273.
  100. Kumar B, Jain R, Sandhu K., et al. Epidemiology of childhood psoriasis: a study of 419 patients from northern India. // Int J Dermatol. 2004 Sep; 43(9):654-8.
  101. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosedpsoriasis in US adults: results from NHANES 2003-2004. J AmAcad Dermatol 2009; 60: 218–224.
  102. Landells I, Paller AS, Pariser D et al. Efficacy and safety of etanercept in children and adolescents aged >= 8 years with severe plaque psoriasis. Eur J Dermatol 2010; 20: 323–328.
  103. Langley RG, Paller AS, Hebert AA et al. Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial. J Am Acad Dermatol 2011; 64: 64–70.
  104. Lara-Corrales I, Xi N, Pope E. Childhood psoriasis treatment: evidencepublished over the last 5 years. Rev Recent Clin Trials 2011; 6: 36–43.
  105. Lofgren S, Krol A. New therapies in pediatric dermatology. Curr Opin Pediatr. 2011;23:399–402.
  106. Lomholt G. Psoriasis. Prewalence, spontaneous course and genetics. A census study on the prevalence of skin diseases in the Faroe lslands. Copenhagen: GEC Gad; 1963.
  107. Lovell DJ, Reiff A, Ilowite NT et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008; 58: 1496–1504.
  108. Lowenthal KE, Horn PJ, Kalb RE. Concurrent use of methotrexate and acitretin revisited. J Dermatolog Treat 2008; 19: 22–26.
  109. Luu M, Cordoro KM. The evolving role of biologics in the treatment of pediatric psoriasis. Skin Therapy Lett 2013; 18: 1–4.
  110. Mahe E, Bodemer C, Pruszkowski A, Teillac-Hamel D, de Prost Y. Cyclosporine in childhood psoriasis. Arch Dermatol 2001; 137: 1532–1533.
  111. Matthews D, Fry L, Powles A, et al. Evidence that a locus for familial psoriasis maps to chromosome 4q. Nat Genet. 1996;14:231-233.
  112. Maverakis E, Miyamura Y, Bowen MP, Correa G, Ono Y, Goodarzi H. Light, including ultraviolet. J Autoimmun. 2001;34:J247–57.
  113. Mazzotta A, Saraceno R, Esposito M, Chimenti S. Etanercept, childhood and long-term safety: a case of five years treatment. Eur J Dermatol 2011;21: 776–777.
  114. McGonagle D, Tan AL, Benjamin M. The nail as a musculoskeletal appendage -implications for an improved understanding of the link between psoriasis and arthritis. Dermatology.2009;218(2):97-102.
  115. Menter MA, Cush JM. Successful treatment of pediatric psoriasis with infliximab. Pediatr Dermatol 2004; 21: 87–88.
  116. Menter MA, Whiting DA, McWilliams J. Resistant childhood psoriasis: an analysis of patients seen in a day-care center. Pediatr Dermatol. 1984; 2:8–12.
  117. Milano A, Bonifazi E. Psoriasis, arthritis, autoimmune hepatitis and dystrophic calcinosis in a 15-year-old girl. Eur J Pediat Dermatol 2009; 19:109–114.
  118. Moretti D, Cianchi I, Vannucci G, Cimaz R, Simonini G. Psoriatic juvenile idiopathic arthritis associated with uveitis: a case report. Case Rep Rheumatol 2013; Epub ahead of print.
  119. Morris A, Rogers M, Fischer G, Williams K. Childhood psoriasis: a clinical review of 1262 cases. Pediatr Dermatol. 2001;18:188–98.
  120. Nair R, Stuart P, Henseler TS, et al. Localization of psoriasis susceptibility locus PSORS1 to a 60kb interval telomeric to HLA- C. Am J Hum Genet. 2000;66:1833-1844.
  121. Nair RP, Henseler T, Jenisch S, et al. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16p, 20p) by genome wide scan. Hum Mol Genet. 1997;6:1349-1356.
  122. Nakamura S, Hashimoto Y, Igawa S et al. Childhood generalized pustular psoriasis treated by preprandial ciclosporin administration: serum cytokine pattern during the course of the disease. Clin Exp Dermatol 2009; 34:e1023–e1024.
  123. Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol. 2005;152:597–615.
  124. NCT02166203?term=ustekinumab+psoriasis&rank=8. (last accessed: 26 June 2014).
  125. Oka A, Tamiya G, Ota M, et al. Association analysis using refined microsatellite markers localises a susceptibility locus for psoriasis vulgaris within a 111kb segment telomeric to the the HLA- C gene. Hum Mol Genet. 1999;8:2165-2170.
  126. Osorio F, Magina S. Phototherapy and photopheresis: old and new indications. Expert Rev Dermatol. 2011;6:613–23.
  127. Otten MH, Prince FH, Ten Cate R et al. Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective? Ann Rheum Dis 2011; 70: 337–340.
  128. Oxford Centre for Evidence-Based Medicine Levels of Evidence. Homepage (May 2001). URL http://www.cebm.net/index.aspx?o=1025. (lastaccessed: 19 February 2009).
  129. Pacifico L, Renzi AM, Chiesa C. Acute guttate psoriasis after streptococcal scarlet fever. Pediatr Dermatol 1993; 10: 388–389.
  130. Paller AS, Eichenfield LF, Langley RG et al. Subgroup analyses of etanercept in pediatric patients with psoriasis. J Am Acad Dermatol 2010; 63:e38–e41.
  131. Paller AS, Siegfried EC, Eichenfield LF et al. Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Dermatol 2010; 63:762–768.
  132. Paller AS, Siegfried EC, Langley RG et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008; 358: 241–251.
  133. Papoutsaki M, Costanzo A, Mazzotta A, Gramiccia T, Soda R, Chimenti S. Etanercept for the treatment of severe childhood psoriasis. Br J Dermatol 2006; 154: 181–183.
  134. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiologyof psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377–385.
  135. Pasic A, Ceovic R, Lipozencic J, et al. Phototherapy in pediatric patients. Pediatr Dermatol. 2003;20:71–7.
  136. Pathak, MA, Jimbow, K, Szabo, G, et al: Sunlight and melanin pigmentation. In: Smith KC (ed.). Photochemical and Photobiological Reviews 1976, Plenum Press, New York. pp 211–39.
  137. Patrizi A, Costa AM, Fiorillo L, Neri I. Perianal streptococcal dermatitis associated with guttate psoriasis and/or balanoposthitis: a study of five cases. Pediatr Dermatol 1994; 11: 168–171.
  138. Pavicic Z, Kmet-Vizitin P, Kansky A. Etretinate in treating juvenile generalized pustular psoriasis. In Farber EM, Cox AJ, eds. Proceedings of the 4th international symposium on psoriasis, Stanford University. University Press, Stanford (CA), 1986: 467.
  139. Pavlovsky M, Baum S, Shpiro D, Pavlovsky L, Pavlotsky F. Narrow band UVB: is it effective and safe for paediatric psoriasis and atopic dermatitis? J Eur Acad Dermatol Venereol. 2011;25:727–9.
  140. Pearce DJ, Stealey KH, Balkrishnan R, Fleischer AB Jr, Feldman SR. Psoriasis treatment in the United States at the end of the 20th century. Int J Dermatol. 2006;45:370–4.
  141. Pedersen OB, Svendesen AJ, Ejstrup L. et al. On the heritability of psoriatic arthritis. Disease concordance among monozygotic and dizygotic twins. Ann Rheum Dis 2008;67(10):1417-1421.
  142. Pereira TM, Vieira AP, Fernandes JC, Antunes H, Basto AS. Anti-TNF-alpha therapy in childhood pustular psoriasis. Dermatology 2006; 213: 350–352.
  143. Pootrakul L, Kalb RE. The management of psoriasis in children and adolescents. G Ital Dermatol Venereol. 2010;145:259–68.
  144. Posso-De Los Rios CJ. Pope E, Lara-Corrales I. A Systematic Review of Systemic Medications for Pustular Psoriasis in Pediatrics. Pediatr Dermatol 2014; 31: 430–439.
  145. Pugashetti R, Koo J. Phototherapy in pediatric patients: choosing the appropriate treatment option. Semin Cutan Med Surg. 2010;29:115–20.
  146. Pugashetti R, Koo J. Phototherapy in Pediatric Patients: Choosing the Appropriate Treatment Option.-2010.-Published by Elsevier Inc. 115 doi:10.1016/j.sder.
  147. Racz E, Kurek D, Kant M, et al. GATA3 expression is decreased in psoriasis and during epidermal regeneration; induction by narrow-band UVB and IL-4. PLoS One. 2011;6:e19806.
  148. Racz E, Prens EP, Kant M, et al. Narrowband ultraviolet B inhibits innate cytosolic double-stranded RNA receptors in psoriatic skin and keratinocytes. Br J Dermatol. 2011;164:838–47.
  149. Racz E, Prens EP, Kurek D, et al. Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways. J Invest Dermatol. 2011;131:1547–58.
  150. Radtke MA, Folster-Holst R, Beikert F, Herberger K, Augustin M. Juvenile psoriasis: rewarding endeavours in contemporary dermatology and pediatrics. G Ital Dermatol Venereol. 2011;146:31–45.
  151. Rahman SI, Siegfried E, Flanagan KH, Armbrecht ES. The methotrexate polyglutamate assay supports the efficacy of methotrexate for severe inflammatory skin disease in children. J Am Acad Dermatol 2014; 70: 252–256.
  152. Ramanan AV, Whitworth P, Baildam EM. Use of methotrexate in juvenile idiopathic arthritis. Arch Dis Child 2003; 88: 197–200.
  153. Raychaudhuri SP, Gross J. A comparative study of pediatric onset psoriasis with adult onset psoriasis. Pediatr Dermatol. 2000;17:174–8.
  154. Raychaudhuri SP, Gross J. A comparative study of pediatric onset psoriasiswith adult onset psoriasis. Pediatr Dermatol 2000; 17: 174–178.
  155. Rosenberg EW, Noah PW, Zanolli MD, Skinner RB Jr, Bond MJ, Crutcher N. Use of rifampin with penicillin and erythromycin in the treatment of psoriasis. Preliminary report. J Am Acad Dermatol 1986; 14: 761–764.
  156. Rosinska D, Wolska H, Jablonska S, Konca I. Etretinate in severe psoriasis of children. Pediatr Dermatol 1988; 5: 266–272.
  157. Rossi-Semerano L, Piram M, Chiaverini C, De Ricaud D, Smahi A, Kone-Paut I. First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra. Pediatrics 2013;132: e1043–e1047.
  158. Rott S, Kǘster RM, Mrowietz U. Successful treatment of severe psoriatic arthritis with infliximab in an 11-year-old child suffering from linear psoriasis along lines of Blaschko. Br J Dermatol 2007; 157:191–192.
  159. Ruiz-Villaverde R, Sanchez-Cano D, Abalos-Medina G. Adolescent plaque psoriasis: our experience using etanercept. J Eur Acad Dermatol Venereol 2009; 23: 976–977.
  160. Russell TJ, Schultes LM, Kuban DJ. Histocompatibility (HLA) antigens associated with protiasis. N Engl J Med. 1972;287:738-743.
  161. Sachdev A, Shwayder T. Suspected rapid-onset neutropenia following etanercept use: disproved following rechallenge and lessons to be learned. Int J Dermatol 2013; 52: 1287– 1288.
  162. Safa G, Loppin M, Bousser AM, Barbarot S. Etanercept in a 7-year-old boy with severe and recalcitrant psoriasis. J Am Acad Dermatol 2007; 56:S19–S20.
  163. Sage RJ, Lim HW. UV-based therapy and vitamin D. Dermatol Ther. 2010; 23:72–81.
  164. Salleras M, Sanchez-Regana M, Umbert P. Congenital erythrodermic psoriasis: case report and literature review. Pediatr Dermatol 1995; 12:231–234.
  165. Sarkar S, Das K, Roychoudhury S, Shrimal A. Pseudotumor cerebri in a child treated with acitretin: a rare occurrence. Indian J Pharmacol 2013; 45: 89–90.
  166. Schachner L, Ling NS, Press S. A statistical analysis of a pediatric dermatology clinic. Pediatr Dermatol. 1983;1:157.
  167. Schachner L.A.,Hansen R.C. Pediatric dermatology / Fourth Edition. – V.1 – 2. - 2011.
  168. Schon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352:1899–912.
  169. Schunter F, Schieferstein G. HLA antigene bei psoriasis vulgaris. Hautarzt. 1974;25:82.
  170. Seignalet J , Clot J, Guilhou JJ, et al. HLA antigens and some immunological parameters in psoriasis. Tiusive Antigens. 1974;4:59.
  171. Shah KN. Diagnosis and treatment of pediatric psoriasis: current andfuture. Am J Clin Dermatol 2013; 14: 195–213.
  172. Shetty GJ, Dhurat RS, Ovhal A, Jerajani HR. Childhood pustular psoriasis successfully treated with sequential therapy. Eur J Pediat Dermatol 2008;18: 213–216.
  173. Siegfried EC, Eichenfield LF, Paller AS, Pariser D, Creamer K, Kricorian G. Intermittent etanercept therapy in pediatric patients with psoriasis. J Am Acad Dermatol 2010; 63: 769– 774.
  174. Simon M, Montezin M, Guerrin M, et al. Characterisation and purification of human corneodesmin, an epidermal basic glycoprotein associated with corneocyte-specific modified desmosomes. J Biol Chem. 1997;272:31770-31776.
  175. Stahle M, Atakan N, Boehncke WH et al. Juvenile psoriasis and its clinicalmanagement: a European expert group consensus. J Dtsch Dermatol Ges 2010; 8: 812–818.
  176. Steeman ASM, Balak DMW, Seyger MMB, Thio HB, Bousema MT.Fumaraten bij een meisje van vijftien jaar met psoriasis!. Nederlands Tijdschrift voor Dermatologie en Venereologie 2012; 22: 308–310.
  177. Stern RS, Nichols KT. Therapy with orally administered methoxsalen and ultraviolet A radiation during childhood increases the risk of basal cell carcinoma. The PUVA Follow-up Study. J Pediatr. 1996;129:915–7.
  178. Sticherling M, Augustin M, Boehncke WH et al. Therapy of psoriasis inchildhood and adolescence - a German expert consensus. J Dtsch Dermatol Ges 2011; 9: 815–823.
  179. Sticherling M. Children and adolescents with psoriasis. What therapy is recommended? Hautarzt 2012; 63: 192–201.
  180. Swanbeck G, Inerot A, Martinsson T, et al. Genetic counselling in psoriasis: empirical data on psoriasis among first-degree relatives of 3095 psoriatic probands. Br J Dermatol. 1997ж137(6):939-942.
  181. Tan Al, Benjamin M, Toumi H, et al. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis -a highresolution MRI and histological study. Rheumatology. 2007;46(2):253-256.
  182. Tan E, Lim D, Rademaker M. Narrowband UVB phototherapy in children: A New Zealand experience. Australas J Dermatol. 2010;51:268–73.
  183. Tay YK, Morelli JG, Weston WL. Experience with UVB phototherapy in children. Pediatr Dermatol. 1996;13:406–9.
  184. Teran CG, Teran-Escalera CN, Balderrama C. A severe case of erythrodermic psoriasis associated with advanced nail and joint manifestations: a case report. J Med Case Rep 2010; 4: 179.
  185. Tiilikainen A, Lassus A, Karvonen J ,et al. Psoriasis and HLA Cw6. Br J Dermatol. 1980;102:179-184.
  186. Tiwari JL, Lowe NJ, Abramovits W, et al. Association of psoriasis with HLA- DR7. Br J Dermatol. 1982;106: 227-230.
  187. Tomfohrde J, Silverman A, Barnes R, et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science. 1994;264:1141-1145.
  188. Torchia D, Terranova M, Fabbri P. Photosensitive psoriasis in a vitiligo patient. J Dermatol 2006; 33: 880–883.
  189. Trembath RS, Clough RL, Rosbotham JL, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome wide search in psoriasis. Hum Mol Genet. 1997;6:813-820.
  190. Umezawa Y, Mabuch T, Ozawa A. Generalized pustular psoriasis in achild: observation of long-term combination therapy with etretinate andcalcipotriol for 16 years. Pediatr Dermatol 2012; 29: 206–208.
  191. Vahavihu K, Ala-Houhala M, Peric M, et al. Narrowband ultraviolet B treatment improves vitamin D balance and alters antimicrobial peptide expression in skin lesions of psoriasis and atopic dermatitis. Br J Dermatol. 2010;163:321–8.
  192. van de Kerkhof PC. Generalized pustular psoriasis in a child. Dermatologica 1985; 170: 244–248.
  193. van der Rhee HJ, van Gelderen HH, Polano MK. Is the use of Ro 10-9359 (Tigason) in children justified? Acta Derm Venereol 1980; 60: 274–275.
  194. Vincent F, Ross JB, Dalton M, Wort AJ. A therapeutic trial of the use of penicillin V or erythromycin with or without rifampin in the treatment of psoriasis. J Am Acad Dermatol 1992; 26: 458–461.
  195. Wahba A, Cohen H. Therapeutic trials with oral colchicine in psoriasis. Acta Derm Venereol 1980;
  196. Wasilewska A, Zoch-Zwierz WM, Tenderenda E, Szynaka B. IgA nephropathy in a girl with psoriasis and seronegative arthritis. Pediatr Dermatol 2008; 25: 408–409.
  197. Watson W, Cann HM, Farber EM, et al. The genetics of psoriasis. Arch Dermatol. 1972;105:197-207.
  198. Weatherhead SC, Farr PM, Jamieson D, et al. Keratinocyte apoptosis in epidermal remodeling and clearance of psoriasis induced by UV radiation. J Invest Dermatol. 2011;131:1916–26.
  199. Weishaupt C, Metze D, Luger TA, Stander S. Treatment of pustular psoriasis with infliximab. J Dtsch Dermatol Ges 2007; 5: 397–399.
  200. White SH, Newcomer VD, Mickey ER, et al. Disturbance of HLA antigen frequency in psoriasis. N Engl J Med. 1972;287:740.
  201. Wright NA, Piggott CD, Eichenfield LF. The role of biologics and other systemic agents in the treatment of pediatric psoriasis. Semin Cutan Med Surg 2010; 29: 20–27.
  202. Xiao T, Li B, He CD, Chen HD. Juvenile generalized pustular psoriasis.J Dermatol 2007; 34: 573–576.
  203. Zachariae H, Kragballe K, Herlin T. Colchicine in generalized pustular psoriasis: clinical response and antibody-dependent cytotoxicity by monocytes and neutrophils. Arch Dermatol Res 1982; 274: 327–333.
  204. Zamberk P, Velazquez D, Campos M, Hernanz JM, Lazaro P. Paediatric psoriasisnarrowband UVB treatment. J Eur Acad Dermatol Venereol. 2010;24:415–9.
  205. Zhou Y, Chaplin DD. Identification in the HLA class I region of a gene expressed late in keratinocyte differentiation. Proc Natl Acad Sci USA. 1993;90:9470-9

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*